PT - JOURNAL ARTICLE AU - Volker Nimmrich AU - Robert Szabo AU - Csaba Nyakas AU - Ivica Granic AU - Klaus G. Reymann AU - Ulrich H. Schröder AU - Gerhard Gross AU - Hans Schoemaker AU - Karsten Wicke AU - Achim Möller AU - Paul Luiten TI - Inhibition of Calpain Prevents <em>N</em>-Methyl-<span class="sc">d</span>-aspartate-Induced Degeneration of the Nucleus Basalis and Associated Behavioral Dysfunction AID - 10.1124/jpet.108.142679 DP - 2008 Nov 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 343--352 VI - 327 IP - 2 4099 - http://jpet.aspetjournals.org/content/327/2/343.short 4100 - http://jpet.aspetjournals.org/content/327/2/343.full SO - J Pharmacol Exp Ther2008 Nov 01; 327 AB - N-Methyl-d-aspartate (NMDA) receptor-mediated excitotoxicity is thought to underlie a variety of neurological disorders, and inhibition of either the NMDA receptor itself, or molecules of the intracellular cascade, may attenuate neurodegeneration in these diseases. Calpain, a calcium-dependent cysteine protease, has been identified as part of such an NMDA receptor-induced excitotoxic signaling pathway. The present study addressed the question of whether inhibition of calpain can prevent neuronal cell death and associated behavioral deficits in a disease-relevant animal model, which is based on excitotoxic lesions of the cholinergic nucleus basalis magnocellularis of Meynert. Excitotoxic lesions of the nucleus basalis with NMDA induced a markedly impaired performance in the novel object recognition test. Treatment with the calpain inhibitor, N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethlyaminomethylphenyl) ethen-1-yl]benzamide (A-705253), dose-dependently prevented the behavioral deficit. Subsequent analysis of choline acetyltransferase in the cortical mantle of the lesioned animals revealed that application of A-705253 dose-dependently and significantly attenuated cholinergic neurodegeneration. Calpain inhibition also significantly diminished the accompanying gliosis, as determined by immunohistochemical analysis of microglia activation. Finally, inhibition of calpain by A-705253 and the peptidic calpain inhibitor N-acetyl-Leu-Leu-Nle-CHO did not impair long-term potentiation in hippocampal slices, indicating that calpain inhibition interrupts NMDA excitotoxicity pathways without interfering with NMDA receptor-mediated signaling involved in cognition. We conclude that inhibition of calpains may represent a valuable strategy for the prevention of excitotoxicity-induced neuronal decline without interfering with the physiological neuronal functions associated with learning and memory processes. Thus, calpain inhibition may be a promising and novel approach for the treatment of various neurodegenerative disorders. The American Society for Pharmacology and Experimental Therapeutics